According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...
In the SURMOUNT-1 trial, obese patients without diabetes who received tirzepatide with monthly lifestyle counseling lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with ...
The findings are congruent with recently reported real-world data that found a 6.9% greater weight loss at 1 year with tirzepatide versus semaglutide. Average weight lost in SURMOUNT-5 was also ...
31.6% of people taking Zepbound achieved at least 25% body weight loss compared to 16.1% of those taking Wegovy. The overall safety profile of Zepbound in SURMOUNT-5 was similar to previously ...
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
Hosted on MSN1mon
Eli Lilly says 'Zepbound superior to Wegovy in head-to-head trialHe emphasized that Zepbound's dual GIP and GLP-1 receptor agonist mechanism makes ... which aligned with previous SURMOUNT studies. The most common side effects for both medications were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback